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Although preventive chemotherapy has been instrumental in reducing schistosomiasis worldwide,  serious 44 
challenges remain. These include the omission of certain groups from mass drug administration campaigns, the 45 
existence of persistent disease hotspots as well as the risk of recrudescent infections. Central to these challenges 46 
is the fact that the currently prescribed diagnostic tools to establish the burden of infection lack sensitivity, 47 
especially in low endemic settings, resulting in an underestimation of the true prevalence of active Schistosoma 48 
infections. This necessitates a re-evaluation and possible adaptation of current WHO-recommended control 49 
strategies. Recently, more targeted interventions and novel approaches have been employed, such as 50 
establishing infection burden by precision mapping to provide high resolution spatial information that delineates 51 
significant variations in schistosomiasis prevalence within a defined geographical area. Such information is 52 
instrumental in guiding targeted intervention campaigns. However, the need for highly accurate diagnostic tools 53 
in such strategies remains a crucial factor that is often neglected. The availability of highly sensitive diagnostic 54 
tests also opens up the possibility of applying sample pooling strategies, to reduce control programme costs. To 55 
achieve interruption of transmission and eventually elimination of schistosomiasis, better local targeting of 56 
preventive chemotherapy in combination with utilising more sensitive diagnostic tools is vital.  57 
 58 
Key-points 59 
* Preventive chemotherapy has been key in reducing the burden of schistosomiasis but serious challenges 60 
remain 61 
 62 
* Current diagnostic tools to detect Schistosoma infections as part of control programmes lack sensitivity 63 
  64 
* Re-evaluation and adaption of current WHO-recommended schistosomiasis control strategies is urgently 65 
needed 66 
 67 
* The use of highly sensitive diagnostic tools is key in breaking the transmission cycle and moving towards 68 




Introduction  70 
Despite years of sustained control efforts, the global burden of schistosomiasis remains high with an estimated 71 
221 million people worldwide requiring preventive chemotherapy of which 90% resides in sub-Saharan Africa 72 
(1). This immense burden is exacerbated by the fact that schistosomiasis is strongly linked to poverty, limited 73 
access to potable water, and lack of adequate sanitation (2). Since 2001, the World Health Organisation (WHO) 74 
has strongly advocated for schistosomiasis morbidity control through preventive chemotherapy (World Health 75 
Assembly resolution 54·19 (3)) with a more recent expanded goal of elimination of schistosomiasis as a public 76 
health problem (World Health Assembly resolution 65·21 (4)).  77 
While there have been successes in reducing the intensity of infections and associated morbidity through 78 
sustained mass drug administration (MDA) campaigns, schistosomiasis remains highly prevalent (5). In regions 79 
that have successfully reduced the intensity of infection to lower thresholds, the currently prescribed diagnostic 80 
tools are no longer reliable for control programmes treating these populations. Especially in areas with a low 81 
infection intensity these methods lack sensitivity and are therefore not able to accurately detect such low 82 
intensity infections and thereby underestimate the prevalence of active Schistosoma infections (6, 7). To break 83 
the cycle of transmission and shift towards sustained elimination of schistosomiasis, changes to the current 84 
global schistosomiasis control strategies are urgently needed (8, 9). The availability of more sensitive diagnostic 85 
tools presents opportunities to revisit these strategies in regions where a break in transmission may be feasible.  86 
Strategic changes to advance the global control of schistosomiasis were discussed at an international workshop 87 
hosted by Leiden University Medical Center in the Netherlands in September 2017. The workshop brought 88 
together representatives from national control programmes, industry, donors and academia (research scientists, 89 
clinicians, and mathematical modellers) to develop a vision for sustained local interruption of transmission and 90 
the eventual successful elimination of schistosomiasis.  91 
Challenges related to the current approach  92 
The WHO’s current strategy for controlling schistosomiasis focuses on reducing disease morbidity and 93 
transmission through periodic, targeted MDA with praziquantel (40 mg/kg body weight) administered to at-risk 94 
populations (10). As part of this strategy, the mean schistosomiasis prevalence is determined in an 95 
‘implementation unit (IU)’; a geographical area where an MDA programme is being rolled-out. This IU can be a 96 
whole district or a sub-district (Figure 1A), for example an administrative, health or education district and it 97 
varies in size from country to country (11).  98 
Usually, in 5-10 sentinel sites within such an IU a parasitological survey is performed to determine the overall 99 
prevalence in the entire IU (Figure 1B) (9, 12). The sentinel site can be a school with 50 children per school 100 
being surveyed. Based on the mean prevalence determined by the survey, the risk of schistosomiasis is 101 
categorised as low (<10%), moderate (≥10% to <50%) or high (≥ 50%) for the whole IU (Figure 1C); a 102 
classification that defines the intervention strategy applied within this geographical area (13). Even though at 103 
sub-district level the burden of infection can be determined in more detail, this strategy does not sufficiently 104 
capture the focality of schistosomiasis, resulting in areas receiving over- or more importantly under-treatment 105 
(12). 106 
Although initial implementation of the WHO MDA strategy has been successful in reducing morbidity (14-16) 107 
there are several opportunities for optimisation. MDA strategies traditionally target school-age children, a group 108 
within which the prevalence of schistosomiasis is often higher compared to other groups and which can be 109 
conveniently reached by programmes at one location (a school). However, this strategy fails to cover other 110 
groups that are at high risk of schistosome infection, for example preschool-age children and adults exposed to 111 
infested water through their occupations (e.g. fishermen, farmers, women doing laundry and irrigation workers) 112 
(17, 18). As such, these groups remain potential active reservoirs for continued transmission in a community. 113 
Preschool-age children are excluded due to safety concerns and poor adherence to praziquantel, although this 114 
concern is likely to be addressed with the development of a paediatric formulation for praziquantel (19). 115 
Likewise, WHO guidelines recommend the inclusion of pregnant and lactating women in MDA campaigns, but 116 
these groups often remain excluded also due to safety concerns despite the growing body of evidence 117 
demonstrating efficacy and safety of praziquantel for their treatment (20, 21). Exclusion of certain groups 118 




The commitment of Merck to support the WHO through the donation of praziquantel for preventive 120 
chemotherapy in school-aged children in Sub-Saharan Africa (22) has been pivotal to schistosomiasis control 121 
efforts. However, with the scale-up of MDA programmes, many African countries have been faced with the 122 
challenge of bridging the gap between the demand for praziquantel and what is available via the donation 123 
programme (23). Moreover, the currently recommended MDA dosage for praziquantel may be leading to 124 
suboptimal cure rates and prolonged low intensity infections within some communities. These consequences 125 
will be even more substantial and pronounced when percentages of population coverage of MDA will be 126 
reduced, leaving larger numbers of infected people untreated.  127 
Additionally, in certain areas control of schistosomiasis is hampered by the existence of ‘persistent hotspots’; 128 
geographical regions where MDA programmes have been in operation for several years, yet remain unable to 129 
achieve the forecasted declines in prevalence or intensity of schistosomiasis (24-27). Persistent hotspots have 130 
been identified across Africa including Kenya (28), Mali (29, 30), Sudan (31) and Tanzania (24, 32). These 131 
hotspots likely require approaches that combine MDA with multi-sectoral efforts such as health education, 132 
improvements to sanitation and potable water supply, environmental and vector control as well as future use of 133 
vaccines (33-37). 134 
Another challenge in the control of schistosomiasis exists in parts of Asia where the prevalent schistosome 135 
species (S. japonicum, S. mekongi and S. malayensis) are known to be zoonotic and have several animal 136 
definitive hosts as a reservoir of infection (38). Also in African schistosomiasis, animal reservoirs have been 137 
described (39, 40). In such areas, the control and elimination of schistosomiasis is even more problematic since 138 
the management of animal reservoirs is imperative (38). In addition, molecular studies have also found evidence 139 
of genetic interactions between human and animal schistosomes within the African continent and the emergence 140 
of hybrid species indicative of some zoonotic spill-over (41, 42).  141 
Classic diagnosis of schistosomiasis as part of control programmes is often still based on parasitological 142 
assessment of urine or stool, depending on the schistosome species endemic in the area. These diagnostic 143 
methods are known to lack sensitivity in detecting infections of low intensity, resulting in an underestimation of 144 
the burden of infection (7). Identifying areas with low infection intensities using accurate diagnostic tools 145 
combined with cost-effective strategies for implementation is essential for achieving elimination of 146 
schistosomiasis. This is also important for dealing with ‘subtle morbidities’ that could have long-term impact on 147 
the quality of life of individuals including effects on cognitive development (43). Control programmes struggle 148 
with how to tackle low prevalence settings where the factors sustaining transmission at lower levels are poorly 149 
understood and interruption of transmission has not yet been achieved (9, 33, 34). In addition, low endemic 150 
areas likely require continuous surveillance with highly sensitive diagnostic tools, as the risk of prematurely 151 
stopping MDA might very well result in infection levels returning to pre-MDA levels shortly after cessation of 152 
MDA (recrudescent infections) (37, 44). As for persistent hotspots, an integrated control approach is likely 153 
required to achieve these epidemiological targets.  154 
Importance of precision mapping and more targeted interventions 155 
Locating exactly where active transmission occurs and which individuals within a community still harbour 156 
living worm pairs, is particularly relevant as schistosomiasis is heterogeneously distributed, meaning that an 157 
endemic region can be considered as a collection of (micro)foci (45). There is a lack of clear guidelines that 158 
account for the potential effects of this natural heterogeneity, or focality, on programme design. Recent studies 159 
by the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) have shown a large 160 
variability in MDA efficacy at the community level (24, 28). Therefore, existing control guidelines need to be 161 
adapted with greater focus on geographical areas of low endemicity that are likely to achieve transmission 162 
interruption. In these areas, sampling grids can be narrowed by increasing the number of sites being sampled; a 163 
concept that has been termed ‘precision mapping’ (12). In order to demonstrate the precision mapping approach 164 
in Cameroon, Tchuem Tchuenté et al exhaustively sampled all schools in two schistosomiasis-endemic districts 165 
representing geographical areas characterised as being low and high with respect to schistosomiasis transmission 166 
(12). This approach produced high-resolution mapping information that showed significant variations in 167 
schistosomiasis prevalence between districts and sub-districts (called implementation units, IU), which would 168 
not have been detected with conventional mapping approaches that are part of the current global control 169 
strategies. Analysis of data from precision mapping can be used to guide targeted and intensified interventions 170 
in high-risk areas, providing a cost-efficient and judicious use of donated praziquantel. Furthermore, this 171 




advantage to specifically target the identification of individuals living in a low-endemic community who 173 
harbour significant intensities of living adult worms (the so called ‘super-spreaders’ (46)).  174 
 Importance of highly sensitive diagnostics 175 
The success of any strategy to tackle schistosomiasis hinges on the ability to obtain an accurate picture of the 176 
burden of infection in a given community, as ‘improvement can only come from accurate measurement’ (Lord 177 
Kelvin, 1883) (47). The necessity of accurate diagnostic tools with high sensitivity in these strategies is often 178 
neglected. To achieve the goal of elimination of schistosomiasis, highly sensitive and specific diagnostic tools, 179 
that ideally are field-applicable, are needed to monitor the burden of infection. 180 
Several diagnostic tools have demonstrated to be useful alternatives compared to conventional diagnostic 181 
methods currently used by national control programmes, such as the widely used field-applicable point-of-care 182 
circulating cathodic antigen (POC-CCA) test (48, 49). Even though this test has been recommended as a 183 
replacement for traditional microscopy (50), it is limited to the detection of intestinal schistosomiasis and still 184 
lacks sensitivity in detecting infections of low intensity (51, 52). A more promising alternative is the highly 185 
sensitive and specific laboratory-based up-converting phosphor lateral flow (UCP-LF) test that detects 186 
Schistosoma circulating anodic antigen (CAA) (53-56). It is a genus-specific test which detects all Schistosoma 187 
species in blood and urine samples, and may potentially be able to detect a single worm pair by increasing 188 
sample volume (56, 57). Furthermore, the UCP-LF CAA test is amenable to pooled sample testing strategies 189 
(58). Individuals whose pooled urine samples are found negative by the UCP-LF CAA test can be assumed to all 190 
be free of schistosome worms, or at least below a set threshold in worm load, while in CAA-positive urine 191 
pools, one or more individuals harbour a worm burden which might be relevant for further transmission. 192 
Individual urine samples can then be subsequently tested to identify infected individuals within a positive 193 
sample pool, in order to only treat infected individuals and thereby save drugs. Compared to more exhaustive 194 
sampling approaches, such pooling strategies can potentially reduce control programme costs (59). Although the 195 
UCP-LF CAA test is still lab-based, steps are underway to develop a more field-applicable version of this test 196 
(55, 58, 60). Clearly, a reliable and easy-to-use rapid diagnostic test is a prerequisite for the development of test-197 
and-treat strategies, with or without pooled sampling, as well as to facilitate the clinical diagnosis of 198 
schistosomiasis at point-of-care settings and the targeted use of praziquantel. 199 
Other more sensitive and specific diagnostics methods include polymerase chain reaction (PCR)-based methods 200 
for the detection of schistosome-specific DNA in clinical samples (urine, faeces or blood) (7, 61). One approach 201 
that has been designed for field use is loop-mediated isothermal amplification (LAMP), an advanced DNA-202 
based detection method that amplifies DNA without a thermocycler and in some instances, can have higher 203 
sensitivity compared to conventional PCR (62-64). Another potentially field-applicable technique is isothermal 204 
recombinase polymerase amplification (RPA) for schistosome-specific DNA detection applicable to both S. 205 
haematobium (65) and S. mansoni (66).  206 
Integrating sensitive diagnostics into an intensified focal test-and-treat strategy 207 
In a theoretical schistosomiasis endemic area, comprised of one or more IUs, where the prevalence of infection 208 
has been determined to be low by standard parasitological methods (i.e. less than 10% overall prevalence and 209 
less than 1% prevalence of heavy infections), an intensified focal test-and-treat strategy, using highly accurate 210 
diagnostic tools, should at least be included to shift transmission dynamics within these geographical areas 211 
towards a break in transmission.  212 
When applying the precision mapping approach in such an area, the burden of infection within an IU should be 213 
estimated from a larger number of sentinel sites, rather than a sampling from 5-10 sites as is conventionally 214 
recommended. This increased sampling from a larger number of sentinel sites would require pooling multiple 215 
samples in order to reduce the total number of tests needed as a cost-saving measure (58, 59). Given the focal 216 
nature of schistosomiasis, sampling designs should also consider proximity to water contact points where 217 
transmission is suspected. 218 
In one scenario discussed at the workshop, an IU at sub-district level can be divided into separate ‘transmission 219 
units’ (TU, Figure 1D); a proposed geographical area limited to one or few transmission sites. So, instead of the 220 
current strategy in which 5-10 sentinel sites within an IU are being sampled, the whole IU is divided into 221 




sampled and tested, leading to a quantitative evaluation of the overall infection burden within each TU. 223 
Mathematical modelling could provide valuable information on the best pooling strategy, taking into 224 
consideration age-groups or risk groups, as well as expected infection levels based on pre-control endemicity 225 
and history of control, to determine optimal pool size (58, 59). Information from existing databases on 226 
correlation between different diagnostic tests could also be used to develop a predictive model to estimate for 227 
example CAA or DNA loads and linking these individual measurements to transmission potential within a given 228 
area. The outcome of testing pooled samples with a highly sensitive diagnostic test in combination with the 229 
predictions of the model(s) would then guide the prevalence thresholds that should be set to determine the 230 
appropriate control strategy that will be embarked on within each TU.  231 
 232 
Figure 1. Schematic representation illustrating the current strategy of sampling within an intervention 233 
unit in comparison to a mapping approach at a smaller level based on a pooled sampling strategy. 234 
Currently, according to the WHO, areas are divided into implementation units (IU) (A) which can vary in size; 235 
for example a whole district (A-i) or a sub-district (A-ii). The burden of infection in each IU is determined and 236 
monitored by sampling from 5-10 sentinel sites (B) using conventional parasitological diagnostic tools. The 237 
burden of infection is then categorised as low, moderate or high for each IU (C). By further dividing sub-district 238 
IUs into smaller transmission units (TU) (D), and instead of sampling from 5-10 sentinel sites applying a 239 
pooling strategy to the whole TU, a bigger area will be sampled from. This results in more accurate data for 240 




Table 1: Proposed treatment strategy based on infection burden  242 
Infection burden established by sampling  Recommended treatment strategy* 
I.   High infection burden   Intense MDA (annual or biannual treatment of all high-risk 
groups as well as community-wide treatment) 
II.  Medium infection burden  Regular MDA (annual community-wide treatment) 
III. Low infection burden (near elimination)  Intensified focal test-and-treat (multiple rounds per year) 
and frequent surveillance, using the most sensitive 
diagnostic tool available in combination with pooled 
sampling  
IV. No infection (anymore)    No MDA, regular surveillance, using the most sensitive 
diagnostic tool available in combination with pooled 
sampling 
* Combined with integrated intervention measures, see text 243 
From the strategy outlined above, we envisage four scenarios that may reflect the burden of infection from 244 
surveying each TU (shown in Table 1). The corresponding recommended strategy should then also be 245 
implemented at TU level. In TUs found to have a high infection burden, for instance potential ‘hotspots’ or 246 
‘persistent hotspots’, intense MDA of yearly or twice-yearly treatment should be rolled out following existing 247 
control strategies. Additional samples should be taken not only from school-age children, but also from high-248 
risk groups (such as fishermen, car-washers, women doing laundry, etc.) and testing stratified according to these 249 
groups. The strategy could be adapted to treatment for each positive group in addition to all school-age children; 250 
and the entire group could be monitored and followed up over a two-year period. For TUs where a medium 251 
infection burden is established, a regular MDA programme of yearly community-wide treatment should be 252 
implemented. In areas where the burden of infection is found to be low, an intensified test-and-treat strategy 253 
with multiple rounds of testing and treating per year should be implemented after identifying the high-risk 254 
groups within each community. In addition, the identification, treatment and monitoring of individuals who still 255 
harbour high worm infections also needs to be taken into account in this strategy. Furthermore, knowledge 256 
about local transmission sites with respect to aquatic biology and social behaviour patterns is indispensable in 257 
tackling and reducing exposure. Individual worm levels could also be included to guide local or regional 258 
interventions. In TUs found to be negative, no MDA would be carried out but groups should be followed-up and 259 
tested over a given period of time using a cost-efficient sample pooling strategy. It would be important to know 260 
if these areas have always been negative or are negative after prolonged control since the monitoring approach 261 
depends on the potential for transmission in the area (best reflected by the pre-control endemicity). Obviously, 262 
all strategies also need to include other integrated multisectoral approaches such as health education, snail 263 
control, and water, sanitation and hygiene (WASH) initiatives. Classic xenomonitoring augmented with DNA 264 
methods that can identify infected snail hosts is especially important to determine environmental risk accurately 265 
(67), as well as monitoring of schistosome infection in locations where zoonotic spill-over may occur. Further 266 
innovations such analysis of water for environmental DNA (eDNA) (68), signatures of schistosomes with taxon 267 
specific probes, could be very powerful to verify putative interruptions of transmission.  268 
At the national level, a surveillance response mechanism would need to monitor these focal test-and-treat 269 
strategies. This includes modelling for prediction and guiding the intervention, monitoring of infection and 270 
mechanisms to evaluate interventions (69). Global positioning system (GPS) mapping could be used to 271 
determine precise locations of infected people of all ages and their households (70). However, privacy issues 272 
need to be taken into consideration. Innovations such as surveying snail environmental DNA (eDNA) in water 273 
bodies (68, 71) are additional tools that can be used to monitor transmission. Lessons can also be learnt from the 274 
Global Polio Eradication Initiative which uses environmental surveillance of poliovirus in sewage to monitor 275 
the virus (72). 276 
After presumed interruption of transmission has been achieved, communities should still, ideally, be monitored 277 
longitudinally using highly sensitive and specific assays using the UCP-LF CAA test and eventually also 278 
serology. After a number of years with no new infections being detected, new-borns and young children would 279 
have to be followed to assess their exposure to schistosomes (44, 73), which could be done through for example 280 
targeted anti-schistosomal antibody testing (74, 75). In addition, the movement of individuals from regions that 281 
are still endemic for schistosomiasis into post-transmission areas would have to be monitored, and infected 282 
individuals promptly treated. The development of commercially available highly sensitive tests would be 283 




Given that current schistosomiasis control programmes in sub-Saharan Africa rely heavily on donated 285 
praziquantel for MDA campaigns, the proposed test-and-treat strategy will enhance cost-efficiency. The 286 
availability of a paediatric praziquantel formulation for young children will further support and strengthen a 287 
community-wide targeted treatment approach. 288 
The successful implementation and efficient rollout of the proposed strategy would hinge on close cooperation 289 
between key international players (such as WHO) and stakeholders within endemic countries. Within these 290 
countries, engagement with national and local authorities would guarantee local ownership and responsibility 291 
for the strategy and its implementation. Targeted implementation at more local levels such as a TU could be 292 
more complex due to logistical challenges and the lack of adequate structures. Therefore, strengthening overall 293 
neglected tropical disease (NTD) coordination structures at national and sub-national levels, including the 294 
building of local capacity, would assure the proper execution of the proposed strategy, as well as effective long-295 
term monitoring, evaluation and overall sustainability. 296 
Additionally, it would be essential that endemic countries adopt and incorporate the strategy into the 297 
development of their NTD master plans. This would be achieved through local and international stakeholders 298 
working closely with endemic country NTD expert committees that are responsible for coordinating the 299 
direction of national NTD goals and policies (including for schistosomiasis) and ensuring that these are in line 300 
with regional and global targets. Combining all these efforts is essential for improved focal targeting of 301 
preventive chemotherapy in combination with more sensitive diagnostic tools in order to achieve interruption of 302 





The persistent global burden of schistosomiasis despite continuous large-scale MDA, requires a rethinking and 305 
revision of both intervention strategies and the diagnostic tools that enable these strategies. Especially in areas 306 
of low infection intensity, non-invasive pooled sample testing with highly accurate diagnostic tools should be 307 
implemented by national control programmes in adapted control strategies that ensure cost-efficiency in 308 
monitoring and evaluation, as well as longer-term surveillance. We believe this will be the way to go to achieve 309 
interruption of transmission and eventually elimination of schistosomiasis.  310 
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